Paclitaxel

Generic Name: Paclitaxel

Brand Names: Abraxane, Taxol, Naveruclif, Pazenir, Apexelsin

Drug Type: Small Molecule

Chemical Formula: C_₄₇H_₅₁NO_₁₄

CAS Number: 33069-62-4

Unique Ingredient Identifier: P88XT4IS4D

Background: Paclitaxel is a chemotherapeutic agent marketed under the brand name Taxol among others. Used as a treatment for various cancers, paclitaxel is a mitotic inhibitor that was first isolated in 1971 from the bark of the Pacific yew tree which contains endophytic fungi that synthesize paclitaxel. It is available as an intravenous solution for injection and the newer formulation contains albumin-bound paclitaxel marketed under the brand name Abraxane.

Indication: Used in the treatment of Kaposi's sarcoma and cancer of the lung, ovarian, and breast. Abraxane® is specfically indicated for the treatment of metastatic breast cancer and locally advanced or metastatic non-small cell lung cancer.

Associated Conditions: Advanced Cervical Cancer, Advanced Head and Neck Cancer, Advanced Ovarian Cancer, Advanced Soft Tissue Sarcoma, Esophageal Cancer, Fallopian Tube Cancer, Gastric Cancer, Kaposi's Sarcoma, Locally Advanced Non-Small Cell Lung Cancer, Metastatic Bladder Cancer, Metastatic Breast Cancer, Metastatic Melanoma, Metastatic Non-Small Cell Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), Ovarian Cancer, Pancreatic Adenocarcinoma Metastatic, Peritoneal Cancer, Recurrent Small Cell Lung Cancer (SCLC), Advanced Bladder cancer, Advanced Thymoma, Metastatic Penile cancer, Refractory Testicular germ cell cancer

Associated Therapies: -

Clinical Trials

Paclitaxel and Trastuzumab With or Without Lapatinib in Treating Patients With Stage II or Stage III Breast Cancer That Can Be Removed by Surgery

Phase 3

Active, not recruiting

Conditions: Male Breast Carcinoma
Stage IIA Breast Cancer AJCC v6 and v7
Stage IIIC Breast Cancer AJCC v7
Stage IIB Breast Cancer AJCC v6 and v7
Stage IIIA Breast Cancer AJCC v7
Stage IIIB Breast Cancer AJCC v7

Interventions: Other: Laboratory Biomarker Analysis
Drug: Lapatinib Ditosylate
Drug: Paclitaxel
Biological: Trastuzumab

First Posted Date: 2008-10-10

Last Posted Date: 2024-12-27

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 305

Registration Number: NCT00770809

Locations: 🇺🇸
Miami Valley Hospital, Dayton, Ohio, United States
🇺🇸
Miami Valley Hospital North, Dayton, Ohio, United States
🇺🇸
Dayton NCI Community Oncology Research Program, Dayton, Ohio, United States

and more 313 locations

Study Evaluating Safety And Tolerability, Solid Tumor

Phase 1

Completed

Conditions: Advanced Malignant Solid Tumors

Interventions: Drug: Neratinib
Drug: Paclitaxel

First Posted Date: 2008-10-08

Last Posted Date: 2018-11-19

Lead Sponsor: Puma Biotechnology, Inc.

Target Recruit Count: 10

Registration Number: NCT00768469

Locations: 🇯🇵
Investigational Site, Tokyo, Japan

A Study to Determine Whether EGFR Status by FISH Can Predict Results in Non Small Cell Lung Cancer (NSCLC) Patients Treated With Cetuximab, Carboplatin and Paclitaxel

Phase 2

Withdrawn

Conditions: Lung Neoplasms
Carcinoma, Non-Small-Cell Lung

Interventions: Drug: Cetuximab
Drug: Paclitaxel
Drug: Carboplatin

First Posted Date: 2008-10-07

Last Posted Date: 2015-10-28

Lead Sponsor: Eli Lilly and Company

Registration Number: NCT00768131

Locations: 🇺🇸
Local Institution, Austin, Texas, United States

A Study of Pemetrexed, Carboplatin and Bevacizumab in Participants With Nonsquamous Non-Small Cell Lung Cancer

Phase 3

Completed

Conditions: Non-small Cell Lung Cancer

Interventions: Drug: Pemetrexed
Drug: Paclitaxel
Drug: Carboplatin
Biological: Bevacizumab

First Posted Date: 2008-09-30

Last Posted Date: 2015-12-21

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 939

Registration Number: NCT00762034

Locations: 🇺🇸
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Milwaukee, Wisconsin, United States

Safety Study of XL147 (SAR245408), in Combination With Paclitaxel and Carboplatin in Adults With Solid Tumors

Phase 1

Completed

Conditions: Cancer
Non-Small Cell Lung Cancer
Endometrial Carcinoma
Ovarian Carcinoma

Interventions: Drug: XL147 (SAR245408),
Drug: paclitaxel
Drug: carboplatin

First Posted Date: 2008-09-22

Last Posted Date: 2013-04-10

Lead Sponsor: Sanofi

Target Recruit Count: 52

Registration Number: NCT00756847

Locations: 🇺🇸
Investigational Site Number, Madison, Wisconsin, United States

Phase II Neoadjuvant in Inflammatory Breast Cancer

Phase 2

Terminated

Conditions: Breast Cancer

Interventions: Drug: Lapatinib
Drug: Paclitaxel
Drug: 5-Fluorouracil (5-FU)
Drug: Epirubicin
Drug: Cyclophosphamide

First Posted Date: 2008-09-22

Last Posted Date: 2014-11-17

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 15

Registration Number: NCT00756470

Locations: 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States

Paclitaxel, Carboplatin Plus Bevacizumab in Pretreated, Advanced or Metastatic Non Small Cell Lung Cancer

Phase 2

Completed

Conditions: Non Small Cell Lung Cancer

Interventions: Drug: Carboplatin
Drug: Bevacizumab
Drug: Paclitaxel

First Posted Date: 2008-09-17

Last Posted Date: 2016-10-04

Lead Sponsor: Hellenic Oncology Research Group

Target Recruit Count: 50

Registration Number: NCT00753909

Locations: 🇬🇷
"Metaxa's" Anticancer Hospital of Piraeus, 1st Dep of Medical Oncology, Athens, Greece
🇬🇷
Air Forces Military Hospital of Athens, Athens, Greece
🇬🇷
"Laikon" General Hospital, Medical Oncology Unit, Propedeutic Dep of Internal Medicine, Athens, Greece

and more 7 locations

Phase 2 Study of REOLYSIN® in Combination With Paclitaxel and Carboplatin in Patients With Head and Neck Carcinoma

Phase 2

Completed

Conditions: Carcinoma, Squamous Cell of the Head and Neck

First Posted Date: 2008-09-16

Last Posted Date: 2014-11-04

Lead Sponsor: Oncolytics Biotech

Target Recruit Count: 14

Registration Number: NCT00753038

Locations: 🇺🇸
Cancer Therapy and Research Center at UTHSCSA, San Antonio, Texas, United States
🇺🇸
Montefiore Medical Center, Bronx, New York, United States

Paclitaxel and Carboplatin Combination as 1st Line Treatment in Ovarian Carcinomas

Phase 1

Completed

Conditions: Ovarian Cancer

Interventions: Drug: Paclitaxel
Drug: Carboplatin

First Posted Date: 2008-09-10

Last Posted Date: 2011-05-23

Lead Sponsor: Hellenic Oncology Research Group

Target Recruit Count: 50

Registration Number: NCT00750386

Locations: 🇬🇷
University General Hospital of Alexandroupolis, Dep of Medical Oncology, Alexandroupolis, Greece
🇬🇷
University Hospital of Crete, Heraklion, Crete, Greece
🇬🇷
"IASO" General Hospital of Athnes, Dep of Medical Oncology, Athens, Greece

and more 9 locations

An Efficacy and Safety Study of MORAb-003 in Platinum-Resistant or Refractory Relapsed Ovarian Cancer

Phase 2

Terminated

Conditions: Ovarian Cancer

Interventions: Drug: 0.9% Saline
Drug: MORAb-003 (farletuzumab)
Drug: Paclitaxel

First Posted Date: 2008-08-20

Last Posted Date: 2017-03-30

Lead Sponsor: Morphotek

Target Recruit Count: 415

Registration Number: NCT00738699

Locations: 🇺🇸
USC/Norris Comprehensive Cancer Center, Los Angeles, California, United States
🇺🇸
Innovative Medical Research of South Florida, Inc., Miami, Florida, United States
🇺🇸
Weinberg Cancer Institute at Franklin Square, Baltimore, Maryland, United States

and more 58 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy